Novo Nordisk's amycretin outshines Wegovy in early obesity study
07 Mar 2024
Clinical ResultPhase 1
Novo Nordisk is making inroads in the development of its next obesity hopeful, unveiling early-stage data that topped previous results for its current blockbuster weight-loss product Wegovy (semaglutide).
Findings from a Phase I study showed that an oral version of amycretin, which targets both the GLP-1 and amylin receptors, led to weight loss of 13.1% after 12 weeks. The results were disclosed Thursday at Novo Nordisk’s capital markets day, with the news, along with other updates from the company, sending shares up more than 5%.
The drugmaker is also working on a subcutaneous version of amycretin, with Phase I data expected next year. Novo Nordisk indicated that those results will define the drug’s clinical development programme.
"Novo has made clear that the amycretin molecule likely will form the foundation of the company's rapidly growing pipeline," remarked Guggenheim analyst Seamus Fernandez.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.